7 completed. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow S*BIO: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia SB939 - Leukemia, Solid Tumours | Phase 1 | Completed | NCIC Clinical Trials Group | 12 | 2010-10-01 | 2023-08-04 |
| A Single and Multiple-Dose Study of SB1578 SB1578, Placebo - Healthy Volunteer | Phase 1 | Completed | S*BIO | 40 | 2010-08-01 | 2012-04-20 |
| A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies SB1518 - Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Completed | S*BIO | 76 | 2008-08-01 | 2012-04-20 |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis SB1518 - Myelofibrosis, Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | S*BIO | 55 | 2008-08-01 | 2012-04-20 |
| A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies SB1518 - Lymphoma, Malignant, Hodgkin's Lymphoma | Phase 1 | Completed | S*BIO | 35 | 2008-07-01 | 2012-04-20 |
| SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors HDAC inhibitor SB939, immunoenzyme technique, immunohistochemistry staining method - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | NCIC Clinical Trials Group | 39 | 2007-09-14 | 2023-08-04 |
| A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine SB939, Azacitidine - Solid Tumors, Hematologic Malignancies | Phase 1 | Completed | S*BIO | 85 | 2007-04-01 | 2012-04-23 |
Myelodysplastic Syndromes (2) · Primary Myelofibrosis (2) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Thrombocythemia, Essential (1)
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (3) · 15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triazatetracyclo(18.3.1.1(2,5).1(14,18))hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (1) · Azacitidine (1) · Chromatography, Liquid (1) · Immunoenzyme Techniques (1) · Immunohistochemistry (1) · Immunologic Techniques (1) · Mass Spectrometry (1) · SB939 compound (1)
United States (5) · Canada (2) · Australia (1) · Singapore (1)
Anas Younes, M.D. (1) · Andrew Roberts, M.D. (1) · Bik To, MD (1) · Boon Cher Goh, M.D. (1) · Charles Chuah, M.D. (1) · George Wilding, M.D. (1) · Guillermo Garcia-Manero, MD (1) · H. Joachim Deeg, M.D (1) · Han Chong Toh, M.D. (1) · John Seymour, M.D. (1) · Lillian L. Siu, MD, FRCPC (1) · Mark J Allison, MD (1) · Martha Wadleigh, MD (1) · Olatoyosi M. Odenike, M.D. (1) · Rami Komrokji, MD (1)
PMID 21285985, PMID 22965964, PMID 23893953, PMID 25762180, PMID 27931243